Skip to Content

Evolva Holding SA en liquidation ELVAF

Morningstar Rating
$0.86 +0.03 (3.63%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ELVAF is trading at a 61% discount.
Price
$0.85
Fair Value
$4.85
Uncertainty
Extreme
1-Star Price
$86.51
5-Star Price
$2.63
Economic Moat
Dczlq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ELVAF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.83
Day Range
$0.860.86
52-Week Range
$0.0620.60
Bid/Ask
$0.76 / $12.85
Market Cap
$5.83 Mil
Volume/Avg
1,228 / 640

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.30
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Evolva Holding SA en liquidation formerly Evolva Holding SA is a biotechnology company. The company is engaged in discovering, developing, and commercializing ingredients and biomanufacturing processes for nutrition, healthcare, and wellness products. Geographically, the company operates in Switzerland and the United States where Switzerland derives a majority of its revenue.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
49

Valuation

Metric
ELVAF
Price/Earnings (Normalized)
Price/Book Value
0.13
Price/Sales
0.30
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ELVAF
Quick Ratio
0.60
Current Ratio
1.49
Interest Coverage
−99.96
Quick Ratio
ELVAF

Profitability

Metric
ELVAF
Return on Assets (Normalized)
−16.96%
Return on Equity (Normalized)
−22.05%
Return on Invested Capital (Normalized)
−17.83%
Return on Assets
ELVAF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDpyd$541.4 Bil
VRTX
Vertex Pharmaceuticals IncJfjqv$110.3 Bil
REGN
Regeneron Pharmaceuticals IncVcymcp$108.4 Bil
MRNA
Moderna IncJhjx$37.2 Bil
ARGX
argenx SE ADRTrql$23.7 Bil
BNTX
BioNTech SE ADRBvhw$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncMvddhzy$19.6 Bil
BMRN
Biomarin Pharmaceutical IncJcvgs$16.7 Bil
RPRX
Royalty Pharma PLC Class ACgqhgd$13.7 Bil
INCY
Incyte CorpKvfvrts$13.5 Bil

Sponsor Center